aTyr plunges as lung disease drug misses main goal in late-stage study

aTyr Pharma

15/09/2025 15:34

Updates

** Shares of drug developer aTyr Pharma ATYR.O fall 81.8% to record low of $1.09

** Co says its drug efzofitimod did not meet the main goal in a late-stage study in patients with pulmonary sarcoidosis

** The trial aimed to show a bigger cut in daily steroid use after 48 weeks versus a placebo

** Patients on the higher dose of the drug reduced use of steroids to an average of 2.79 mg/kg a day, compared with 3.52 mg/kg on placebo, a difference that was not statistically significant

** Pulmonary sarcoidosis is an inflammatory condition affecting the lungs and lymph nodes

** ATYR says it plans to engage with the U.S. FDA to determine the path forward for the drug

** "Ultimately, while the primary endpoint was missed, we do not believe the door is shut for efzofitimod in pulmonary sarcoidosis with a potential "green-light" for filing after regulator engagement"- Piper Sandler

** Including session moves, stock down 71.6% YTD

 (Reporting by Christy Santhosh and Sneha S K)

 ((Christy.Santhosh@thomsonreuters.com))